Programme Thesis
The EIC Accelerator provides non-dilutive grant and blended finance (up to €2.5M) to high-risk, deep-tech startups and SMEs developing breakthrough innovations with significant market-creating potential, particularly in health, biotech, and AI. It exists to bridge the funding gap between research and commercialisation, supporting European and select international ventures that can scale globally and generate societal impact.
Selection Criteria
- Eligibility: Must be a for-profit SME (or startup) registered in an EU Member State or Horizon Europe associated country; single-entity or consortium; no more than 50% of the work subcontracted.
- Innovation: Groundbreaking, market-creating innovation with clear technological differentiation and IP strategy (patent, trade secret, or regulatory exclusivity).
- Market potential: Large addressable market, clear go-to-market plan, and evidence of customer validation or early traction.
- Team: Balanced team with technical, business, and operational expertise; founder commitment and ability to execute.
- Risk and impact: High-risk/high-reward profile; societal or environmental impact aligned with EU priorities (e.g., Green Deal, digital health).
- Financial viability: Realistic budget, co-investment readiness (for blended finance), and sustainable business model.
- Scoring: Evaluated on a 0–5 scale across three blocks (innovation, market, team); minimum threshold 4/5 in each block to proceed to interview.
Past Winners / Cohort Profiles
Past winners include deep-tech biotech and AI startups such as Qure.ai (AI radiology), Iktos (AI drug discovery), and Peptomyc (cancer therapeutics). Typical profiles: post-revenue or near-revenue, with a patent portfolio, strong scientific advisory board, and a clear commercialisation roadmap. Many have raised follow-on VC funding. The EIC Accelerator favours ventures that are already incorporated (SME) and have some initial traction (prototype, pilot, or early sales).
Ideal Candidate Fingerprint
A deep-tech startup (SME) with a registered company in an EU/Horizon Europe country, a patented or patent-pending breakthrough technology, a multidisciplinary team (scientific founder + business co-founder), early revenue or pilot partnerships, and a clear plan to scale into global markets. The innovation should be at TRL 5–8 and address a pressing societal challenge with strong EU policy alignment.
Recommended Framing
Eniola should frame his CCT model and IMPRINT platform as a breakthrough AI-driven pharmacological framework for addiction treatment, with a clear path to commercialisation via a spin-off company (e.g., ZYCO Ltd). He must emphasise the validated preclinical results (85.8% encoding reduction), the provisional patent, and endorsements from leading neuroscientists (Berridge, Gershman, Daw) to demonstrate scientific credibility. However, the major red flag is that he is not yet incorporated in an EU country and has no co-founder with business expertise; he should either incorporate in an EU state (e.g., Austria via his planned MSc) or partner with an EU-based SME to apply as a subcontractor.
Watch Out
Not an EU/Horizon Europe-associated country entity (Nigerian independent researcher); no company incorporation; no business co-founder; low TRL (preclinical, no clinical data); no revenue or pilot customers; the programme typically funds SMEs, not individual researchers. The deadline (Oct 2026) may be too soon for incorporation and team building.